TScan Therapeutics (NASDAQ:TCRX) Downgraded to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of TScan Therapeutics (NASDAQ:TCRX) from a sell rating to a strong sell rating in a research note published on Saturday morning.

Other analysts have also issued research reports about the company. Wedbush increased their price target on TScan Therapeutics from $4.00 to $5.00 and gave the company an “outperform” rating in a report on Thursday, March 5th. Weiss Ratings restated a “sell (d-)” rating on shares of TScan Therapeutics in a report on Tuesday, April 21st. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $6.00.

TScan Therapeutics Trading Up 4.1%

TCRX stock opened at $1.26 on Friday. The firm has a fifty day moving average price of $1.11 and a 200 day moving average price of $1.15. TScan Therapeutics has a fifty-two week low of $0.88 and a fifty-two week high of $2.57. The company has a debt-to-equity ratio of 0.34, a quick ratio of 8.41 and a current ratio of 6.65. The firm has a market cap of $71.69 million, a PE ratio of -1.31 and a beta of 1.06.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, meeting the consensus estimate of ($0.22). TScan Therapeutics had a negative return on equity of 91.94% and a negative net margin of 1,360.61%.The company had revenue of $0.98 million for the quarter, compared to analyst estimates of $2.50 million. Sell-side analysts anticipate that TScan Therapeutics will post -1.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TScan Therapeutics

Several hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its position in TScan Therapeutics by 7.8% in the 3rd quarter. Vanguard Group Inc. now owns 2,317,916 shares of the company’s stock valued at $4,219,000 after acquiring an additional 168,540 shares during the last quarter. Aberdeen Group plc grew its position in TScan Therapeutics by 31.8% in the 4th quarter. Aberdeen Group plc now owns 1,785,241 shares of the company’s stock valued at $1,785,000 after acquiring an additional 430,421 shares during the last quarter. Renaissance Technologies LLC grew its position in TScan Therapeutics by 37.5% in the 4th quarter. Renaissance Technologies LLC now owns 1,141,069 shares of the company’s stock valued at $1,141,000 after acquiring an additional 311,150 shares during the last quarter. Two Sigma Investments LP grew its position in TScan Therapeutics by 14.9% in the 3rd quarter. Two Sigma Investments LP now owns 419,404 shares of the company’s stock valued at $763,000 after acquiring an additional 54,370 shares during the last quarter. Finally, Citadel Advisors LLC grew its position in TScan Therapeutics by 78.4% in the 3rd quarter. Citadel Advisors LLC now owns 390,747 shares of the company’s stock valued at $711,000 after acquiring an additional 171,760 shares during the last quarter. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics News Roundup

Here are the key news stories impacting TScan Therapeutics this week:

• Positive Sentiment: HC Wainwright improved its FY2030 EPS estimate for TScan Therapeutics to ($0.07) from ($0.09), suggesting a slightly better long-term earnings trajectory.
• Neutral Sentiment: The analyst left the broader view of TScan’s business still deeply loss-making, with forecasts showing negative EPS through at least FY2030.
• Negative Sentiment: HC Wainwright lowered its 2026, 2027, 2028, and 2029 EPS estimates, including FY2026 to ($0.88) from ($0.76) and FY2027 to ($0.87) from ($0.79), which points to weaker near- and mid-term profitability expectations.

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.